# OnCo record medac (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/medac/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "medac" ;
  schema:name "medac"@en ;
  schema:alternateName "medac GmbH"@en, "medac Pharma"@en ;
  schema:description "medac is a German family-owned pharmaceutical company whose alkylating agent treosulfan, long used in Europe, was approved by the FDA in 2025 as conditioning treatment before stem cell transplantation in acute myeloid leukaemia and myelodysplastic syndromes."@en ;
  schema:url <https://onco.cc/companies/medac/>, <https://www.medac.de/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Medac> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1915776> ;
  schema:citation <https://www.medac.de/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/cell-therapy/> ;
  onco:drugs <https://onco.cc/drugs/treosulfan/> .